Molecular and immunologic mechanisms of cancer pathogenesis in solid organ transplant recipients

American Journal of Transplantation

Volumn 8, Issue 11, 2008, Pages 2205-2211

  Martinez, O M ^a   De Gruijl, F R ^b  

^a STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

EBV; Posttransplant malignancies; PTLD; Rapamycin; Skin cancer

Indexed keywords

GAMMA INTERFERON; IMMUNOSUPPRESSIVE AGENT; INTERLEUKIN 12; TRANSFORMING GROWTH FACTOR BETA; VASCULOTROPIN;

CD4+ T LYMPHOCYTE; CELL GROWTH; EPSTEIN BARR VIRUS; GRAFT REJECTION; HUMAN; IMMUNE SYSTEM; IMMUNOGENICITY; LYMPHOPROLIFERATIVE DISEASE; MALIGNANT NEOPLASTIC DISEASE; NONHUMAN; ORGAN TRANSPLANTATION; PATHOGENESIS; PRIORITY JOURNAL; RECIPIENT; SHORT SURVEY; SKIN CANCER; TUMOR CELL;

ANIMALS; ANTINEOPLASTIC AGENTS; DNA REPAIR; HERPESVIRUS 4, HUMAN; HUMANS; IMMUNE SYSTEM; IMMUNOSUPPRESSIVE AGENTS; LYMPHOPROLIFERATIVE DISORDERS; MODELS, BIOLOGICAL; NEOPLASMS; ORGAN TRANSPLANTATION; RECURRENCE; SKIN NEOPLASMS;

EID: 53749107531     PISSN: 16006135     EISSN: 16006143     Source Type: Journal    
DOI: 10.1111/j.1600-6143.2008.02368.x     Document Type: Short Survey

References (45)

1. Burnet FM. Cancer-a biologic approach. Brit Med J 1957 1 : 841 847.
2. Thomas L. Cellular and humoral aspects of the hypersensitive states. New York : Hoeber-Harper, 1959.
3. Dunn GP, Bruce AT, Ikeda H, Old LJ, Schreiber RD. Cancer immunoediting: From immmunosurveillance to tumor escape. Nat Immunol 2002 3 : 991 998.
4. Nagy S, Gyulai R, Kemeny L, Szenohradszky P, Dobozy A. Iatrogenic Kaposi's sarcoma: HHV8 positivity persists but the tumors regress almost completely without immunosuppressive therapy. Transplantation 2000 27 : 2230 2231.
5. Kuijken I, Bouwes Bavinck JN. Skin cancer risk associated with immunosuppressive therapy in organ transplant recipients: Epidemiology and proposed mechanisms. Bio Drugs 2000 14 : 319 329.
6. + T lymphocytes in the circulation of pediatric transplant recipients. Transplantation 2002 74 : 501 505.
7. Fisher MS, Kripke ML. Systemic alteration induced in mice by ultraviolet light irradiation and its relationship to ultraviolet carcinogenesis. Proc Natl Acad Sci USA 1977 74 : 1688 1692.
8. Schwarz T. 25 years of UV-induced immunosuppression mediated by T cells-from disregarded T suppressor cells to highly respected regulatory T cells. Photochem Photobiol 2008 84 : 10 18.
9. Koebel CM, Vermi W, Swann JB et al. Adaptive immunity maintains occult cancer in an equilibrium state. Nature 2007 450 : 903 907.
10. Snow AL, Martinez OM. Epstein Barr virus: Evasive maneuvers in the development of PTLD. Am J Transplant 2007 7 : 271 277.
11. Snow Al, Lambert SL, Natkunam Y, Esquivel CO, Krams SM, Martinez OM. EBV can protect latently infected B cell lymphomas from death receptor-induced apoptosis. J Immunol 2006 177 : 3283 3293.
12. Lampros TD, Cobanoglu A, Parker F, Ratkovec R, Norman DJ, Hershberger R. Squamous and basal cell carinoma in heart transplant recipients. J Heart Lung Transplant 1998 17 : 586 591.
13. Renaldi M, Pellegrini C, D'Armini et al. Neoplastic disease after heart transplantation: Single center experience. Eur J Cardiothorax Surg 2001 19 : 696 701.
14. Swinnen LJ, Costanzo-Nordin MR, Risher SG et al. Increased incidence of lymphoproliferative disorder after immunosuppression with the monoclonal antibody OKT3 in cardiac-transplant recipients. N Engl J Med 1990 323 : 1723 1728.
15. Leverrier S, Bergamaschi D, Ghali L et al. Role of HPV E6 proteins in preventing UVB-induced release of pro-apoptotic factors form the mitochondria. Apoptosis 2007 12 : 549 560.
16. Gabet AS, Accardi R, Bellopede A et al. Impairment of the telomere/telomerase system and genomic instability are associated with keratinocyte immortalization induced by the skin human papillomavirus type 38. FASEB J 2008 22 : 622 632.
17. Kelly GE, Meikle W, Sheil AG. Scheduled and unscheduled DNA synthesis in epidermal cells of hairless mice treated with immunosuppressive drugs and UVB-UVA irradiation. Br J Dermatol 1987 117 : 429 440.
18. Yarosh DB, Pena AV, Nay SL, Canning MT, Brown DA. Calcineurin inhibitors decrease DNA repair and apoptosis in human keratinocytes following ultraviolet B irradiation. J Invest Dermatol 2005 125 : 1020 1025.
19. Koehl GE, Andrassy J, Guba M et al. Rapamycin protects allografts from rejection while simultaneously attacking tumors in immunosuppressed mice. Transplantation 2004 77 : 1319 1326.
20. O'Donovan P, Perrett CM, Zhang X et al. Azathioprine and UVA light generate mutagenic oxidative DNA damage. Science 2005 309 : 1871 1874.
21. Offman J, Opelz G, Doehler B et al. Defective DNA mismatch repair in acute myeloid leukemia/myelodysplastic syndrome after organ transplantation. Blood 2004 104 : 822 828.
22. Harwood CA, Swale VJ, Bataille VA et al. An association between sebaceous carcinoma and microsatellite instability in immunosuppressed organ transplant recipients. J Invest Dermatol 2001 116 : 246 253.
23. de Graaf YG, Rebel H, Elghalbzouri A et al. More epidermal p53 patches adjacent to skin carcinomas in renal transplant recipients than in immunocompetent patients: the role of azathioprine. Exp Dermatol 2008. Epub ahead of print Nov 2. 2007.
24. Remenyik E, Wikonkál NM, Zhang W, Paliwal V, Brash DE. Antigen-specific immunity does not mediate acute regression of UVB-induced p53-mutant clones. Oncogene 2003 22 : 6369 6376.
25. Mathew T, Kreis H, Friend P. Two-year incidence of malignancy in sirolimus-treated renal transplant recipients: Results from five multicenter studies. Clin Transplant 2004 18 : 446 449.
26. Tosato G, Tanner J, Jones KD, Revel M, Pike SE. Identification of interleukin-6 as an autocrine growth factor for Epstein-Barr virus-immortalized B cells. J Virol 1990 64 : 3033 3041.
27. Scali G, Quinto I, Ruocco MR et al. Expression of exogenous interleukin 6 in human Epstein Barr virus B cells confers growth advantage and in vivo tumorigenicity. J Exp Med 1990 172 : 61 68.
28. Tosato G, Jones K, Breinig MK, McWilliams HP, McKnight JL. Interleukin 6 production in posttransplant lymphoproliferative disease. J Clin Invest 1993 91 : 2806 2814.
29. Baiocchi OC, Colleoni GW, Caballero OL et al. Epstein-Barr viral load, interleukin 6 and interleukin 10 levels in postransplant lymphoproliferative disease: A nested case-control study in a renal transplant cohort. Leuk Lymphoma 2005 46 : 533 539.
30. Tanner JE, Meneszes J. Interleukin 6 and Epstein-Barr virus induction by cyclosporine A: Potential role in lymphoproliferative disease. Blood 1994 84 : 3956 3964.
31. Swinnen LJ, Fisher RI. OKT3 monoclonal antibodies induce interleukin 6 and interleukin 10: A possible cause of lymphoproliferative disorders associated with transplantation. Curr Opin Nephrol Hypertens 1993 2 : 670 678.
32. Haddad E, Paczesny S, Leblond V et al. Treatment of B lymphoproliferative disorder with a monoclonal anti-interleukin 6 antibody in 12 patients: A multicenter phase 1-2 clinical trial. Blood 2001 15 : 1590 1597.
33. Kim J, Modlin RL, Moy RL et al. IL-10 production in cutaneous basal and squamous cell carcinomas. A mechanism for evading the local T cell immune response. J Immunol 1995 155 : 2240 2247.
34. Alamartine E, Berthoux P, Mariat C, Cambazard F, Berthoux F. Interleukin 10 promoter polymorphisms and susceptibility to skin squamous cell carcinoma after renal transplantation. J Invest Dermatol 2003 120 : 99 103.
35. Lambert SL, Martinez OM. Latent membrane protein 1 of Epstein-Barr virus activates PI3K to induce production of interleukin 10. J Immunol 2007 179 : 8225 8234.
36. Beatty PR, Krams SM, Martinez OM. Involvement of IL-10 in the autonomous growth of EBV transformed B cell lines. J Immunol 1997 158 : 4045 4051.
37. Nepomuceno RR, Balatoni CE, Natkunam Y, Snow AL, Krams SM, Martinez OM. Rapamycin inhibits the interleukin 10 signal transduction pathway and the growth of Epstein Barr virus B-cell lymphomas. Cancer Res 2003 65 : 4472 4480.
38. Martinez OM, Villanueva JC, Lawrence-Miyasaki L, Quinn MB, Cox K, Krams SM. Viral and immunologic aspects of Epstein-Barr virus infection in pediatric liver transplant recipients. Transplantation 1995 27 : 519 524.
39. Babel N, Bergopoulos A, Trappe RU et al. Evidence for genetic susceptibility towards development of posttransplant lymphoproliferative disorder in solid organ recipients. Transplantation 2007 84 : 387 391.
40. Kerbel RS. Tumor angiogenesis. New Engl J Med 2008 358 : 2039 2049.
41. Noonan DM, De Lerma Barbaro A, Vannini N, Mortara L, Albini A. Inflammation, inflammatory cells and angiogenesis: Decisions and indecisions. Cancer Metastasis Rev 2008 27 : 31 40.
42. Blobe GC, Schiemann WP, Lodish HF. Role of transforming growth factor beta in human disease. N Engl J Med 2000 342 : 1350 1358.
43. Hojo M, Morimoto T, Maluccio M et al. Cyclosporine induces cancer progression by a cell-autonomous mechanism. Nature 1999 397 : 530 534.
44. Maluccio M, Sharma V, Lagman M et al. Tacrolimus enhances transforming growth factor beta 1 expression and promotes tumor progression. Transplantation 2003 76 : 597 602.
45. Li AG, Lu SL, Han G, Hoot KE, Want XJ. Role of TGF-β in skin inflammation and carcinogenesis. Mol Carcinog 2006 45 : 389 396.